Intellectus Partners’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $330K | Buy |
6,057
+212
| +4% | +$11.2K | 0.06% | 248 |
|
|
2026
Q1 | $278K | Hold |
5,845
| – | – | 0.06% | 250 |
|
|
2025
Q4 | $307K | Buy |
5,845
+200
| +4% | +$12K | 0.06% | 236 |
|
|
2025
Q3 | $366K | Sell |
5,645
-200
| -3% | -$11.5K | 0.07% | 219 |
|
|
2025
Q2 | $284K | Buy |
+5,845
| New | +$226K | 0.06% | 232 |
|
|
2025
Q1 | – | Sell |
-7,131
| Closed | -$281K | – | 276 |
|
|
2024
Q4 | $281K | Buy |
7,131
+250
| +4% | +$11.8K | 0.06% | 229 |
|
|
2024
Q3 | $323K | Buy |
6,881
+125
| +2% | +$6.34K | 0.08% | 212 |
|
|
2024
Q2 | $365K | Sell |
6,756
-1,245
| -16% | -$72K | 0.1% | 200 |
|
|
2024
Q1 | $545K | Sell |
8,001
-705
| -8% | -$50.5K | 0.14% | 178 |
|
|
2023
Q4 | $545K | Buy |
8,706
+150
| +2% | +$8.29K | 0.16% | 171 |
|
|
2023
Q3 | $388K | Buy |
8,556
+650
| +8% | +$33.6K | 0.12% | 193 |
|
|
2023
Q2 | $444K | Buy |
7,906
+50
| +0.6% | +$2.84K | 0.13% | 187 |
|
|
2023
Q1 | $355K | Buy |
7,856
+200
| +3% | +$9.71K | 0.11% | 192 |
|
|
2022
Q4 | $311K | Sell |
7,656
-364
| -5% | -$19.3K | 0.11% | 205 |
|
|
2022
Q3 | $524K | Sell |
8,020
-820
| -9% | -$59.4K | 0.19% | 151 |
|
|
2022
Q2 | $537K | Sell |
8,840
-1,050
| -11% | -$61.7K | 0.18% | 149 |
|
|
2022
Q1 | $621K | Sell |
9,890
-1,000
| -9% | -$62.8K | 0.19% | 144 |
|
|
2021
Q4 | $825K | Sell |
10,890
-280
| -3% | -$24.5K | 0.21% | 126 |
|
|
2021
Q3 | $1.25M | Buy |
11,170
+125
| +1% | +$15.7K | 0.3% | 88 |
|
|
2021
Q2 | $1.79M | Buy |
11,045
+875
| +9% | +$106K | 0.4% | 58 |
|
|
2021
Q1 | $1.24M | Buy |
10,170
+1,200
| +13% | +$181K | 0.34% | 78 |
|
|
2020
Q4 | $1.37M | Sell |
8,970
-475
| -5% | -$56.1K | 0.41% | 74 |
|
|
2020
Q3 | $790K | Buy |
9,445
+370
| +4% | +$32.8K | 0.3% | 105 |
|
|
2020
Q2 | $667K | Buy |
9,075
+30
| +0.3% | +$1.75K | 0.26% | 120 |
|
|
2020
Q1 | $384K | Buy |
9,045
+2,325
| +35% | +$120K | 0.18% | 140 |
|
|
2019
Q4 | $409K | Buy |
+6,720
| New | +$367K | 0.17% | 158 |
|
|
2019
Q2 | – | Sell |
-1,350
| Closed | -$48K | – | 220 |
|
|
2019
Q1 | $48K | Buy |
1,350
+850
| +170% | +$29.4K | 0.02% | 259 |
|
|
2018
Q4 | $14K | Hold |
500
| – | – | 0.01% | 188 |
|
|
2018
Q3 | $22K | Sell |
500
-150
| -23% | -$7.86K | 0.01% | 422 |
|
|
2018
Q2 | $38K | Buy |
+650
| New | +$37K | 0.01% | 366 |
|
|
2017
Q3 | – | Sell |
-425
| Closed | -$7K | – | 782 |
|
|
2017
Q2 | $7K | Hold |
425
| – | – | ﹤0.01% | 632 |
|
|
2017
Q1 | $9K | Buy |
425
+100
| +31% | +$1.96K | ﹤0.01% | 548 |
|
|
2016
Q4 | $7K | Buy |
+325
| New | +$6.07K | ﹤0.01% | 555 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Intellectus Partners's CRSP Position: Q2 2026 in Review
Intellectus Partners increased its CRISPR Therapeutics (CRSP) stake by 3.6% in Q2 2026, buying an estimated $11.2K and bringing the position to 6,057 shares worth $330K. The position accounts for 0.06% of the portfolio, ranked #248.
Intellectus Partners first reported a position in CRSP in Q4 2016 and has held it in 33 quarters since. The position peaked at $1.79M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Intellectus Partners held 6,057 shares of CRISPR Therapeutics worth $330K as of Q2 2026.
- Intellectus Partners bought 212 CRISPR Therapeutics shares in Q2 2026, an estimated $11.2K.
- CRISPR Therapeutics made up 0.06% of Intellectus Partners's portfolio in Q2 2026, its #248 holding.
- Intellectus Partners first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 33 quarters since.
- Intellectus Partners's CRISPR Therapeutics position peaked at $1.79M in Q2 2021.
- 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.